Outcomes and Indicators Sample Clauses

Outcomes and Indicators. The indicators set out within this Local Area Agreement are all taken from the new National Indicator set and fall into three categories:
Sample 1Sample 2
AutoNDA by SimpleDocs
Outcomes and Indicators. This includes a template for each of the North Ayrshire Outcomes. Specific information relating to each Outcome is included, such as the relevant National Outcome; Community Plan Priority; Local Context; and Indicators to measure progress over time. A table is included in each template, illustrating past trend data and future targets for each of the Indicators. This document is updated annually.
Sample 1Sample 2
Outcomes and Indicators. Outcome Indicator Results Reduce the number of households in need by improving access to Affordable Housing that is sound, suitable and sustainable for households in need. Number of Households no longer in housing need as a result of Investment in Affordable Housing. 136 new households funded for new construction or repair. Over 4,000 households received grants through the Provincial Home Repair and Home Modification programs. Increase the number of housing supports provided to victims of family violence to enable them to leave violent situations. Number of victims of family violence who were able to leave violent situations as a result of investments under the agreement. Funding for victims of family violence totaling over $2 million was utilized to fund the construction of an additional 16 units in Corner Brook while also supporting repairs to benefit 35 other units that serve victims of violence. Increase the resources available to address the Housing needs of households in need by encouraging contributions by others, including the private and not-for-profit sectors Additional dollars generated through local partnerships toward addressing housing need as a result of the Investment in Affordable Housing Data to be captured following completion of IAH Projects. From 2011-14, $5,531,364 in owner equity and $2,855,084 in mortgage financing have been committed for new affordable housing. Reduce the demand for services and institutional living by increasing and extending independent living for households in need being seniors and persons with disabilities The number of seniors or persons with disabilities who are able to remain living independently. Close to 4,000 households received structural and related component repairs. Average client is approximately 70 years old and has an income of approximately $14,288.. Over 12,000 seniors have received assistance since 2011. Xxxxxx training of skilled labour by supporting apprenticeships in the residential housing sector. Description of activities/initiatives to promote or support IAH apprenticeships. NLHC has added a requirement for proponents to indicate whether they will be hiring apprentices for their construction activities. Investment in Affordable Housing 2014-19 | 3/31/2018 Reduce the number of households in need by improving access to Affordable Housing that is sound, suitable and sustainable for households in need. Number of households no longer in housing need as a result of Program H-1: Seniors New Cons...
Sample 1
Outcomes and Indicators. 4.1) Young people enjoy living in the Borders and make a positive contribution within their community. Indicator(s) Source Frequency of Update Baseline (baseline year) Target Timescale Owner % satisfaction (young people) with life in the Borders YP Household Survey Notes/Guidance : % Young people who feel they make a positive contribution in their community YP household Survey Notes/Guidance : Eco-Schools statistics? ELL Annual 2nd Green : 2 Green Flag - 4 Silver – 23 Bronze – 28 (2006/07) 2nd Green : 3 Green Flag - 17 Silver – 19 Bronze – 36 2009/10 Notes/Guidance : 100% schools with an award by 2009/10? Number of young people who are victims of crime perpetrated by other young people. Number of children participating in giving their views in sessions with the Children’s Champion 2008/09 Xxxxx Xxxxxx Notes/Guidance : Number of youth work opportunities available split by type and area Local Data Annual Xxxxxxxx Xxxxxx Notes/Guidance : Not all population centres are currently covered Participation of young people in these opportunities Local Data Annual 25% increase Xxxxxxxx Xxxxxx Notes/Guidance : National CLD activity survey is the only existing baseline – requirement to create a year long reporting system Multi media opportunities available to give young people a voice Local Data Annual 52 wired programmes 12 Y.O.B pages (2007/09) 52 wired programmes 12 Y.O.B pages 2008/09 Xxxx Xxxxx Notes/Guidance : Number of attendances by young people at arts/cultural activities Local Data Annual Xxxx XxxXxxxx Notes/Guidance : Number of schools with a School/Pupil Council E&LL- Citizenship Questionnaire Annual ? 2008/09 10% increase 20011/12 Percentage of young people consulted by School/Pupil Councils E&LL- Citizenship Questionnaire Annual ? 2008/09 10% increase 20011/12 Number of young people participating in exchange visits E&LL- Citizenship Questionnaire Annual ? 2008/09 10% increase 20011/12 Percentage of young people involved in inter- school links, national and inter-national E&LL- Citizenship Questionnaire Annual ? 2008/09 10% increase 20011/12 Percentage of young people involved in community projects E&LL- Citizenship Questionnaire Annual ? 2008/09 10% increase 20011/12 Notes/Guidance :
Sample 1

Related to Outcomes and Indicators

  • Trials The Ship shall run the following test and trials:

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to FDA or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and for studies submitted to regulatory authorities for approval, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Outcomes Secondary: Career pathway students will: have career goals designated on SEOP, earn concurrent college credit while in high school, achieve a state competency certificate and while completing high school graduation requirements.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Timelines a) Timelines may be extended by mutual consent of the parties.

  • Product Changes Vocera shall have the right, in its absolute discretion, without liability to End User, to update to provide new functionality or otherwise change the design of any Product or to discontinue the manufacture or sale of any Product. Vocera shall notify End User at least 90 days prior to the delivery of any Product which incorporates a change that adversely affects form, fit or function (“Material Change”). Vocera shall also notify End User at least 90 days prior to the discontinuance of manufacture of any Product. Notification will be made as soon as reasonably practical for changes associated with regulatory or health and safety issues.

Time is Money Join Law Insider Premium to draft better contracts faster.